Septoplasty & Septal Deviation Correction — Cost, Top Hospitals & Success Rates | MyMedicPlus

The nasal septum is the central partition of the nose, composed anteriorly of the quadrangular cartilage and posteriorly of the perpendicular plate of the ethmoid bone and the vomer. Ideally situated in the midline, the septum divides the nasal cavity into two roughly equal passages. A deviated nasal septum (DNS) is a lateral or S-shaped displacement of the septum from the midline — one of the most common anatomical variations in the human body, with population studies suggesting clinically significant deviation in 20–35% of individuals.

DNS may be congenital (resulting from intrauterine positional moulding or birth trauma) or acquired (nasal fractures, sports injuries, or prior nasal surgery). The clinical significance of a deviation depends on its location, severity, and the concomitant state of the nasal turbinates — patients with a deviated septum and compensatory inferior turbinate hypertrophy on the contralateral side may have bilateral functional obstruction.

Septoplasty is the surgical procedure that straightens the deviated septum by selectively removing, repositioning, or reshaping the deviated cartilage and bone while preserving the structural support of the nose. It differs from rhinoplasty, which primarily addresses the external appearance of the nose, though the two are frequently combined as a septo-rhinoplasty when both functional improvement and cosmetic reshaping are desired.

The SNOT-22 (Sino-Nasal Outcome Test-22) is the internationally validated patient-reported outcome measure for rhinological conditions. A clinically meaningful improvement after septoplasty is defined as a reduction of 9 or more points on the SNOT-22 scale; published studies report mean SNOT-22 improvements of 17–25 points after septoplasty, confirming robust functional benefit in appropriately selected patients.

Septoplasty addresses structural nasal obstruction arising from the septum and is indicated in the following clinical scenarios:

• Primary nasal airway obstruction: The core indication. Patients describe persistent unilateral or bilateral nasal blockage, mouth breathing, and reduced exercise tolerance. Obstruction is typically worse on one side (corresponding to the convex side of the deviation) and may alternate sides due to the nasal cycle.
• Septal contact points: Paradoxical curvature of the septum or a prominent septal spur may contact the lateral nasal wall or inferior turbinate, triggering chronic rhinitis symptoms, sneezing, and headache (contact point headache). Surgical removal of the contact point resolves symptoms.
• Sleep-disordered breathing: Septal deviation is a contributing anatomical factor in snoring and, in some patients, obstructive sleep apnoea. Septoplasty alone rarely cures established OSA but meaningfully reduces AHI (apnoea-hypopnoea index) when combined with turbinate surgery and CPAP tolerance is improved after nasal airway restoration.
• Recurrent sinusitis: Septal deviation that narrows the ostiomeatal complex (the drainage pathway of the maxillary, frontal, and ethmoid sinuses) predisposes to recurrent or chronic rhinosinusitis. Septoplasty, often combined with functional endoscopic sinus surgery (FESS), corrects the anatomical obstruction to sinus drainage.
• Epistaxis (nosebleeds): Prominent septal spurs or deviated areas cause turbulent airflow and drying of the local mucosa, leading to recurrent anterior epistaxis. Septoplasty to remove the spur addresses the underlying anatomical cause.
• Cosmetic deformity with functional impairment: When a visibly crooked nose is accompanied by functional obstruction, septo-rhinoplasty addresses both components. When cosmetic concern is the sole motivation and no functional obstruction exists, rhinoplasty alone (without septoplasty) is appropriate.

Appropriate patient selection for septoplasty requires a structured pre-operative assessment:

• Age threshold: Septoplasty for primary nasal obstruction is generally deferred until nasal growth is complete — approximately age 17–18 in females and 18–20 in males. Earlier surgery risks disruption of septal growth centres with consequent saddle nose deformity. Emergency septoplasty for traumatic septal haematoma is an exception and is performed at any age.
• Symptom duration and severity: Nasal obstruction should be persistent (present on most days for at least 3 months), functionally impairing, and not adequately controlled by medical therapy. A SNOT-22 score above 20 is a commonly used threshold for surgical candidacy.
• Failed medical therapy: A minimum 6–8 week trial of topical intranasal corticosteroid spray (e.g., fluticasone propionate 50 mcg per nostril twice daily) should precede surgical planning. If turbinate hypertrophy contributes significantly to obstruction, a decongestant challenge (xylometazoline 0.1% spray) with repeat anterior rhinoscopy helps differentiate structural septum-related obstruction from reversible mucosal swelling.
• Nasal endoscopy and imaging: Anterior rhinoscopy and flexible or rigid nasal endoscopy confirm the site and extent of deviation, assess turbinate size, and identify nasal polyps or other pathology. CT of the sinuses in the coronal plane is indicated when recurrent sinusitis is a co-existing indication or when the anatomy is complex prior to combined surgery.
• Anaesthetic fitness: Standalone septoplasty is routinely performed under general anaesthesia. The procedure is typically 45–90 minutes; septo-rhinoplasty may extend to 3–5 hours. Standard pre-operative cardiovascular and haematological screening applies.

Septoplasty encompasses several technical approaches, chosen based on the site and complexity of the deviation:

• Endonasal (closed) septoplasty: The standard approach. A Killian or hemitransfixion incision is made inside the nostril, the mucoperichondrial flaps are elevated from both sides of the cartilaginous septum, and the deviated cartilage and bone are removed, scored, repositioned, or reshaped. The overlying mucosa is preserved intact. No external scars. Excellent visualisation is provided by modern headlights and rigid 0-degree nasal endoscopes (endoscope-assisted septoplasty), which reveal posterior deviations that may be missed with the naked eye.
• External (open) septoplasty: Access is achieved through a columellar transcolumellar incision connecting the two marginal (intranasal) incisions. The nasal skin is elevated off the underlying osteocartilaginous framework, providing complete visualisation of the entire dorsal septum. Preferred when concurrent rhinoplasty, spreader graft placement, or complex caudal septal reconstruction is planned. The columellar scar is typically imperceptible at 6–12 months.
• Cartilage corrections: The quadrangular cartilage forms the anterior septum and dorsal support. Deviations are corrected by partial excision, morselisation (cross-hatching), or cartilage scoring (weakening the convex surface to straighten). Crucially, a minimum dorsal and caudal L-strut of 10–15 mm must be preserved to maintain tip support and nasal bridge stability.
• Bony corrections: Posterior deviations involving the perpendicular plate of the ethmoid and vomer are corrected by submucosal resection of the deviated bony plates under endoscopic visualisation, avoiding nasal floor disruption.
• Spreader grafts: Strips of harvested septal cartilage placed between the dorsal septum and the upper lateral cartilages. Correct internal nasal valve narrowing (a common co-existing obstruction site), preserve the dorsal aesthetic line (preventing post-operative saddle nose contour), and provide structural support to the middle vault. Standard in open septo-rhinoplasty and increasingly used in endonasal approaches for comprehensive functional correction.
• Inferior turbinate reduction: Inferior turbinate hypertrophy — commonly bilateral and compensatory (larger on the side opposite to the deviation) — frequently coexists with DNS and must be addressed concurrently for optimal functional outcomes. Techniques include lateral outfracture (manually displacing the turbinate laterally to widen the airway, with no tissue removal), submucosal resection (SMR) (removal of the bony turbinate with preservation of the mucosal lining), or radiofrequency turbinate ablation (controlled submucosal scarring that reduces turbinate volume). Outfracture alone has the highest relapse rate; SMR and radiofrequency turbinoplasty offer more durable results.
• Septo-rhinoplasty: Combined functional and cosmetic nasal surgery. The septoplasty provides functional improvement and harvested cartilage for rhinoplasty grafts; the rhinoplasty addresses external nasal shape. Combined procedures are more cost-effective and have a single recovery period. Careful planning is required to ensure that cosmetic manoeuvres (dorsal reduction, osteotomies) do not destabilise the functional correction.

Septoplasty delivers well-documented functional improvements across multiple quality-of-life domains:

• Nasal airway restoration: The primary benefit. Peak nasal inspiratory flow (PNIF) and acoustic rhinometry studies consistently demonstrate significant objective improvement after septoplasty. Clinically, most patients describe dramatic improvement in ease of breathing through the nose within the first 2–6 weeks after surgery, as post-operative swelling resolves.
• SNOT-22 outcome: The SNOT-22 nasal quality-of-life instrument shows clinically and statistically significant improvement in the majority of patients. Published systematic reviews report mean pre-operative SNOT-22 scores of 40–55 (out of 110) dropping to 15–25 at 6–12 months post-operatively — a magnitude of improvement comparable to that seen with hip or knee arthroplasty in terms of patient-reported benefit.
• Sleep quality: Restoration of nasal breathing reduces snoring, improves sleep architecture, and enhances CPAP tolerance in patients with co-existing OSA. Post-operative polysomnography studies demonstrate AHI reduction averaging 30–45% when septoplasty is combined with turbinate reduction.
• Headache resolution: Patients with contact-point headache (septal spur contacting the turbinate) frequently experience complete or significant headache resolution after septoplasty with spur removal.
• Durable results: Properly performed septoplasty — preserving the L-strut and stabilising the caudal septum — produces durable functional benefit. Long-term follow-up studies at 5–10 years demonstrate sustained SNOT-22 improvement in the majority of operated patients, with recurrence rates below 10%.

Septoplasty is generally a low-risk procedure, but specific complications must be discussed in pre-operative consent:

• Septal perforation: A through-and-through hole in the nasal septum resulting from bilateral mucosal tears at the same level during flap elevation. Small perforations may be asymptomatic; larger perforations cause crusting, epistaxis, whistling during breathing, and a saddling of the nasal dorsum from progressive septal necrosis. Prevention relies on meticulous mucosal flap elevation with cold instruments; repair is technically challenging and involves mucosal rotational flaps, cartilage grafting, or silicone septal buttons.
• Bleeding and epistaxis: Intraoperative bleeding is expected and controlled with electrocautery and vasoconstriction. Post-operative epistaxis requiring re-intervention occurs in approximately 1–3% of cases. Patients taking aspirin or NSAIDs must discontinue these 10–14 days before surgery.
• Infection: Rare after septoplasty (less than 1%) due to the rich nasal vascularity and routine post-operative antibiotic prophylaxis. Septal haematoma — collection of blood between the mucosal flaps — can become infected (septal abscess) if not promptly drained. Recognition of septal haematoma (bilateral fluctuant septal swelling) within the first 24–48 hours and urgent drainage is mandatory.
• Saddle nose deformity: Loss of dorsal support from over-resection of the L-strut, or from unsupported excessive dorsal reduction in concurrent rhinoplasty, produces a depression of the nasal bridge (saddle deformity). Prevention requires preserving at least 10–15 mm of the dorsal and caudal L-strut and using spreader grafts for additional dorsal support.
• Persistent obstruction: Approximately 10–20% of patients report incomplete resolution of nasal obstruction. Contributing factors include inadequate turbinate reduction, unrecognised nasal valve collapse, post-operative adhesions (synechiae), or scarring at the surgical site. Revision septoplasty or functional revision rhinoplasty may be required.
• Changes in nasal sensation: Transient hyposmia (reduced sense of smell) from post-operative mucosal swelling is common and resolves within 4–8 weeks. Permanent anosmia is exceedingly rare.

The recovery after septoplasty follows a predictable trajectory with structured milestones:

• Immediately post-operatively (day 0–1): Absorbable internal sutures close the mucosal flaps. Non-absorbable quilting sutures or bilateral silicone septal splints may be placed to prevent haematoma formation and hold the flaps in apposition. Nasal packing (absorptive foam or inflatable balloon) may be used in selected cases for haemostasis, typically removed at 24–48 hours. Patients experience significant nasal congestion, mild bleeding, and facial pressure in the first 24 hours.
• First week: Nasal splints (if used) are removed at 5–7 days. Saline nasal irrigation is started twice daily to clear crusting and prevent synechia formation. Patients should avoid nose blowing, strenuous exercise, and bending over for the first 2 weeks. Return to office work is possible at 5–7 days.
• 6-week review: The landmark recovery milestone. The majority of post-operative mucosal oedema has resolved and the functional benefit of the septoplasty is clinically evident by 6 weeks. A SNOT-22 questionnaire administered at this visit provides a validated record of functional improvement. Nasal endoscopy confirms septal position, mucosal healing, and absence of adhesions.
• External rhinoplasty (if combined): External nasal splints and tapes applied at surgery are removed at 7–10 days. Significant swelling of the nasal tip persists for 3–6 months; the final rhinoplasty result is assessed at 12 months.
• Long-term follow-up: A repeat SNOT-22 assessment at 6–12 months post-operatively provides standardised documentation of long-term outcome and is requested by many institutional audit programmes. Persistent symptoms beyond 6 months warrant re-evaluation for residual deviation, turbinate regrowth, or nasal valve collapse.

The cost of septoplasty depends on whether it is performed as a functional procedure (potentially covered by insurance), as a combined septo-rhinoplasty, and the geographic location of the treating centre:

• Insurance and NHS coverage: Septoplasty for documented nasal obstruction unresponsive to medical therapy is covered by most national health systems and private insurance plans when supported by objective evidence (nasal endoscopy, PNIF measurement, trial of intranasal steroids). In the UK, NHS septoplasty is available through ENT referral; waiting times vary by NHS trust (typically 3–12 months for non-urgent cases). In the US, insurance coverage is nearly universal for medically necessary septoplasty; pre-authorisation and documentation of failed medical management are typically required.
• Private / out-of-pocket (standalone septoplasty): USD 3,500–7,000 in the US (surgeon, anaesthesia, facility fees inclusive). USD 2,500–5,000 in Western Europe. USD 1,000–2,500 at internationally accredited ENT and plastic surgery centres in India, Thailand, Turkey, and Mexico.
• Septo-rhinoplasty (combined functional and cosmetic): The cosmetic rhinoplasty component is typically not covered by insurance and adds USD 3,000–8,000 to the total cost. Combined septo-rhinoplasty costs USD 7,000–18,000 in the US and Western Europe; USD 2,500–7,000 at leading medical tourism destinations (South Korea, Turkey, Iran, India) where rhinoplasty is a major surgical specialty.
• Revision septoplasty: More complex than primary surgery due to scar tissue, altered anatomy, and potentially limited residual cartilage. Costs are typically 30–50% higher than primary septoplasty and usually require open approach and cartilage grafting from auricular or costal rib sources.

Before surgical septoplasty, several non-surgical measures should be maximised to manage symptoms and, in milder cases, may provide sufficient relief:

• Intranasal corticosteroid sprays: The first-line medical treatment for nasal obstruction. Fluticasone propionate, mometasone furoate, and budesonide reduce mucosal oedema and turbinate hypertrophy. While they do not correct anatomical septal deviation, they address the inflammatory and mucosal component of obstruction that frequently coexists with DNS. A minimum 6–8 week trial is standard before surgical planning. Published evidence suggests 30–40% of patients with mild-to-moderate DNS achieve adequate symptom control with topical steroids alone.
• Nasal saline irrigation: Regular high-volume nasal saline irrigation (e.g., neti pot or squeeze bottle) moisturises mucosa, clears crusting and allergens, and reduces nasal congestion. Adjunctive rather than curative for structural deviation, but significantly reduces the symptom burden in many patients and is recommended both as a pre-operative treatment and as indefinite post-operative maintenance.
• Nasal dilators: Internal nasal dilators (e.g., Mute snoring device, Breathe Right strips) mechanically open the nasal valve and anterior nasal passage. Particularly useful for patients with nasal valve collapse contributing to obstruction alongside septal deviation. Not suitable as a long-term substitute for surgery but serve as a useful adjunct during the decision-making period and for patients unfit for surgery.
• Decongestants: Topical decongestants (oxymetazoline, xylometazoline) provide short-term relief of nasal congestion by vasoconstriction of the nasal mucosa. Use should be limited to fewer than 5 consecutive days to avoid rhinitis medicamentosa (rebound congestion from dependency). Oral pseudoephedrine (where available) is less effective and carries cardiovascular risks at higher doses.
• CPAP therapy for associated OSA: For patients with co-existing obstructive sleep apnoea, CPAP therapy effectively treats the respiratory consequences of airway obstruction without surgery. It does not address the underlying septal anatomy; patients who tolerate CPAP well may prefer to defer or avoid septoplasty, while those who cannot tolerate CPAP due to nasal obstruction benefit from septoplasty to improve mask fit and CPAP adherence.
• Allergy management: Allergic rhinitis contributes significantly to turbinate hypertrophy and nasal obstruction; allergen immunotherapy and antihistamines reduce the mucosal component of obstruction and may defer or reduce the need for surgical intervention in patients whose primary driver is allergic rather than structural.